Current position of 5HT3 antagonists and the additional value of NK1 antagonists;: a new class of antiemetics

被引:17
|
作者
de Wit, R
机构
[1] Erasmus Univ, Med Ctr, Dept Med Oncol, NL-3008 AE Rotterdam, Netherlands
[2] Rotterdam Canc Inst, NL-3008 AE Rotterdam, Netherlands
关键词
antiemetics; 5HT(3) antagonists; NK1; antagonists; neurokinine receptor antagonists; substance P;
D O I
10.1038/sj.bjc.6601033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The advent of the 5HT(3) receptor antagonists (5HT(3) antagonists) in the 1990 s and the combination with dexamethasone has resulted in acute emesis protection in 70% of patients receiving highly emetogenic chemotherapy. Despite complete protection in the acute phase, however, 40% of patients as yet have symptoms in the delayed phase. 5HT(3) antagonists and dexamethasone are only modestly effective in this delayed phase. Moreover, the antiemetic protection over repeated cycles is not sustained. Neurokinine 1 receptor antagonists (NK1 antagonists) belong to a new class of antiemetic agents that specifically target the NK1 receptor, which is involved in both the acute and, particularly, the delayed phase of emesis. Clinical studies have demonstrated that the addition of NK1 antagonists to dual therapy with a 5HT(3) antagonist plus dexamethasone improves the acute emesis protection by a further 10-15%. In the delayed phase, the proportion of patients remaining free of emesis increases by even 20-30%. Since the effectiveness of this triplet combination was found to be sustained over six cycles of chemotherapy, the chance for an individual patient to remain completely protected during both the acute and the delayed phase over six chemotherapy cycles is nearly doubled.
引用
收藏
页码:1823 / 1827
页数:5
相关论文
共 50 条
  • [21] Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case–control study
    Olivier Mir
    Jean-Philippe Durand
    Pascaline Boudou-Rouquette
    Julie Giroux
    Romain Coriat
    Anatole Cessot
    Stanislas Ropert
    François Goldwasser
    Raphaël Gaillard
    Supportive Care in Cancer, 2012, 20 : 2235 - 2239
  • [22] One failed clinical trial (of 5HT3 antagonists) does not invalidate the concept
    Foerster, Matti
    Baron, Ralf
    PAIN, 2012, 153 (02) : 263 - 264
  • [23] Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
    deBoerDennert, M
    deWit, R
    Schmitz, PIM
    Djontono, J
    vanBeurden, V
    Stoter, G
    Verweij, J
    BRITISH JOURNAL OF CANCER, 1997, 76 (08) : 1055 - 1061
  • [24] 5HT3 ANTAGONISTS - A ROLE IN IRRITABLE-BOWEL-SYNDROME AND NONULCER DYSPEPSIA
    MAXTON, DG
    HAIGH, CG
    WHORWELL, PJ
    GUT, 1991, 32 (10) : A1228 - A1228
  • [25] Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
    M de Boer-Dennert
    R de Wit
    PIM Schmitz
    J Djontono
    V v Beurden
    G Stoter
    J Verweij
    British Journal of Cancer, 1997, 76 : 1055 - 1061
  • [26] BLOCKADE OF ACQUISITION OF DRUG-CONDITIONED PLACE AVERSION BY 5HT3 ANTAGONISTS
    ACQUAS, E
    CARBONI, E
    GARAU, L
    DICHIARA, G
    PSYCHOPHARMACOLOGY, 1990, 100 (04) : 459 - 463
  • [27] New insights into the antidepressant actions of substance P (NK1 receptor) antagonists
    Rupniak, NMJ
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2002, 80 (05) : 489 - 494
  • [28] Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study
    Mir, Olivier
    Durand, Jean-Philippe
    Boudou-Rouquette, Pascaline
    Giroux, Julie
    Coriat, Romain
    Cessot, Anatole
    Ropert, Stanislas
    Goldwasser, Francois
    Gaillard, Raphael
    SUPPORTIVE CARE IN CANCER, 2012, 20 (09) : 2235 - 2239
  • [29] Design, Synthesis, and Optimization of Balanced Dual NK1/NK3 Receptor Antagonists
    Hanessian, Stephen
    Jennequin, Thomas
    Boyer, Nicolas
    Babonneau, Vincent
    Soma, Udaykumar
    la Cour, Clotilde Mannoury
    Millan, Mark J.
    De Nanteuil, Guillaume
    ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (05): : 550 - 555
  • [30] Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia
    Catalani, Maria Pia
    Alvaro, Giuseppe
    Bernasconi, Giovanni
    Bettini, Ezio
    Bromidge, Steven M.
    Heer, Jag
    Tedesco, Giovanna
    Tommasi, Simona
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (22) : 6899 - 6904